Once- versus twice-daily direct oral anticoagulants after ischemic stroke in atrial fibrillation – A post-hoc analysis of the ELAN trial
Open Access
- 11 August 2025
- journal article
- Published by Oxford University Press (OUP) in European Stroke Journal
Abstract
Introduction: Whether the risk-benefit profile of once-daily versus twice-daily direct oral anticoagulants (DOAC) differs after atrial fibrillation(AF)-associated ischemic stroke is unclear. We explored this in a post-hoc analysis of ELAN trial data (NCT03148457). Patients and methods: We compared the risk of the primary outcome (recurrent ischemic stroke, systemic embolism, intracranial hemorrhage (ICH), major extracranial bleeding, vascular death) from treatment initiation to the trial’s 90-day follow-up in participants treated with once-daily or twice-daily DOAC after AF-associated stroke using Firth’s logistic and Cox proportional hazards regression in unadjusted, inverse-probability-of-treatment-weighted and augmented-inverse-probability-weighted models to address confounding. Secondary outcomes were the primary outcome components and non-major bleeding. We calculated the net clinical benefit (NCB) of twice-daily over once-daily DOAC by subtracting the weighted rate of excess bleeding attributable to twice-daily DOAC from the rate of excess ischemic events possibly prevented by twice-daily DOAC. Results: We analyzed 1890/2013 (94%) participants (median age 77 years, 45% female), of whom 384 (20%) received once-daily and 1506 (80%) twice-daily DOAC. The primary outcome occurred in 64 (3.4%) participants, and did not differ between DOAC types in logistic (OR unadjusted 0.89 (95% CI 0.50–1.66); OR weighted 1.34 (0.71–2.79); OR augmented 1.45 (0.81–3.21); twice-daily vs once-daily DOAC) nor in Cox models. We identified no clear differences in any secondary outcome. NCB analysis revealed a near-neutral net effect of twice-daily versus once-daily DOAC (+0.28 to +0.67 weighted events possibly prevented/100 person-months for ICH weights 1.5–3.3). Discussion and conclusion: The risk-benefit profile of once-daily versus twice-daily DOAC after AF-associated ischemic stroke does not seem to differ.Keywords
Funding Information
- Schweizerische Herzstiftung
- Intramural Research Fund for Cardiovascular Diseases of the National Cerebral and Cardiovascular Center, Japan (20-4-5)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (32003B_169975)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (32003B_197009)
- Stroke Association (2017/02)
This publication has 33 references indexed in Scilit:
- Clinically relevant non-major bleeding with oral anticoagulants: non-major may not be trivial2018
- Once- or twice-daily non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A meta-analysis of randomized controlled trialsJournal of the Formosan Medical Association, 2017
- Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial FibrillationJAMA Internal Medicine, 2016
- Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studiesStatistics in Medicine, 2015
- Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherenceEP Europace, 2015
- Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc scoreThrombosis and Haemostasis, 2015
- Twice- or Once-Daily Dosing of Novel Oral Anticoagulants for Stroke Prevention: A Fixed-Effects Meta-Analysis with Predefined Heterogeneity Quality CriteriaPLOS ONE, 2014
- Balancing the Benefits and Risks of 2 Doses of Dabigatran Compared With Warfarin in Atrial FibrillationJACC, 2013
- Net Clinical Benefit of Adding Clopidogrel to Aspirin Therapy in Patients With Atrial Fibrillation for Whom Vitamin K Antagonists Are UnsuitableAnnals of Internal Medicine, 2011
- The Net Clinical Benefit of Warfarin Anticoagulation in Atrial FibrillationAnnals of Internal Medicine, 2009